Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 4/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 3/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948146 | 1.00 | AKR1B1 (0.36) | AKR1B1TSHRAPEX1ERN1NPC1 | |
| SCHEMBL18073886 | 0.86 | TSHR (0.41) | AKR1B1TSHRNPC1RAB9AHPGD | |
| SCHEMBL22342294 | 0.83 | TSHR (0.39) | AKR1B1TSHRNPC1RAB9AHPGD | |
| SCHEMBL1349442 | 0.80 | APEX1 (0.53) | AKR1B1TSHRAPEX1ERN1PDK2 | |
| SCHEMBL28965365 | 0.79 | ALDH1A1 (0.41) | TSHRHPGDSMN1; SMN2KDM1AKDM1B | |
| SCHEMBL29363756 | 0.79 | PDK2 (0.37) | TSHRERN1NPC1RAB9AHPGD | |
| SCHEMBL29429741 | 0.79 | TSHR (0.35) | TSHRERN1NPC1RAB9AHPGD | |
| SCHEMBL22165559 | 0.79 | TSHR (0.35) | TSHRERN1NPC1RAB9AHPGD | |
| SCHEMBL263907 | 0.79 | PDK2 (0.37) | TSHRERN1NPC1RAB9AHPGD | |
| SCHEMBL25205090 | 0.75 | HSD17B10 (0.41) | AKR1B1TSHRERN1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| US-12543500-B2 | Light emitting element | SAMSUNG DISPLAY CO., LTD. (KR) | 2026-02-03 | — | — | US | disclosed |
| EP-4077318-B1 | BENZIMIDAZOLE DIMERS AS MODULATORS OF STING | CTXT PTY LTD (AU) | 2025-10-15 | — | — | EP | disclosed |
| US-12415785-B2 | Compound modulators of sting | CTXT PTY LTD (AU) | 2025-09-16 | — | — | US | disclosed |
| US-20240343740-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2024-10-17 | — | — | US | disclosed |
| CN-114478603-B | Organic boron condensed ring compound containing branch molecular structure and organic electroluminescent device | 中国科学院长春应用化学研究所 | 2024-05-31 | — | — | CN | disclosed |
| EP-4341255-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | Eli Lilly and Company (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-117355517-A | Macrocyclic glucagon-like peptide 1 receptor agonists | 伊莱利利公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230165131-A1 | LIGHT EMITTING ELEMENT | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-20230165131-A1 | LIGHT EMITTING ELEMENT | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-8592426-B2 | Aryl-benzocycloalkyl amide derivatives | Hoffmann—La Roche Inc. (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2658848-A1 | NEW BIARYL AMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-11-06 | — | — | EP | disclosed |
| CN-103328436-A | Novel aryl-benzocycloalkylamide derivatives | HOFFMANN LA ROCHE | 2013-09-25 | — | — | CN | disclosed |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | US | disclosed |
| WO-2012101011-A2 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012089601-A1 | NEW BIARYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-07-05 | — | — | WO | disclosed |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-06-28 | — | — | US | disclosed |
| US-20110084230-A1 | Process for Synthesizing Organoelemental Compounds | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20110084230-A1 | Process for Synthesizing Organoelemental Compounds | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2011-04-14 | — | — | US | disclosed |
| WO-2007113294-A1 | PROCESS FOR SYNTHESIZING ORGANOELEMENTAL COMPOUNDS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343740-A1 | MACROCYCLIC GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS | GLP1R, GCGR, GIPR | AKR1B1 1454/4885TSHR 99/4885APEX1 3877/4885 |
| US-12543500-B2 | Light emitting element | CRY1, CRY2, CTNNA1 | AKR1B1 2664/4885TSHR 1512/4885APEX1 318/4885 |
| US-12415785-B2 | Compound modulators of sting | STING1, IRF3, MAVS | AKR1B1 4283/4885TSHR 4301/4885APEX1 229/4885 |
| US-20130018055-A1 | NEW ARYL-BENZOCYCLOALKYL AMIDE DERIVATIVES | CYP1A1, AHR, CYP1B1 | AKR1B1 502/4885TSHR 445/4885APEX1 2356/4885 |
| US-20260132112-A1 | COMPOUNDS | STING1, IRF3, CGAS | AKR1B1 1921/4885TSHR 1389/4885APEX1 263/4885 |
| US-20110084230-A1 | Process for Synthesizing Organoelemental Compounds | CHRM1, CHRM2, MLX | AKR1B1 737/4885TSHR 290/4885APEX1 3820/4885 |
| US-20120165338-A1 | NEW BIARYL AMIDE DERIVATIVES | BICRA, HDAC10, BRD7 | AKR1B1 1040/4885TSHR 260/4885APEX1 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.